Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
Richard Teofilo Atallah,1 Maria Virginia Castanos,2,3 Richard Najac,2 Eric Donnenfeld41Rutgers New Jersey Medical School, Newark, NJ, USA; 2Department of Research, Eye and Ear Infirmary of Mount Sinai, New York, NY, USA; 3Department of Ophthalmology, New York Eye & Ear Infirmary of Mount Sin...
Guardado en:
Autores principales: | Atallah RT, Castanos MV, Najac R, Donnenfeld E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8553e4c7ca3145ed8b719629231c4b3e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016) -
Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019) -
The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian J, et al.
Publicado: (2020) -
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021) -
Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett IV, et al.
Publicado: (2018)